Specialized tumor board recommendation

OTHER3 trials

Sponsors

University of California, San Francisco

Conditions

Adult GlioblastomaAstrocytomaCancerDiffuse Intrinsic Pontine Glioma (DIPG)GlioblastomaGliomaGlioma of BrainHemispheric

Unknown Phase

Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma

CompletedNCT02060890

University of California, San FranciscoAdult Glioblastoma

Start: 2014-08-31End: 2017-05-10Updated: 2023-12-12

Molecular Profiling for Individualized Treatment Plan for DIPG

CompletedNCT02274987

University of California, San FranciscoDiffuse Intrinsic Pontine Glioma (DIPG)

Start: 2014-09-16End: 2019-02-24Updated: 2022-11-04

Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma

CompletedNCT03739372

University of California, San FranciscoAstrocytoma, Cancer, Glioblastoma +5

Start: 2018-11-28End: 2026-05-01Updated: 2026-08-11

Related Papers

Rational combination platform trial design for children and young adults with diffuse midline glioma: A report from PNOC

Neuro-Oncology2023-12-202 citations

INNV-16. CNS-TAP TOOL RECOMMENDATIONS OF TARGETED ANTI-CANCER AGENTS COMPARED TO THOSE SELECTED BY A MULTIDISCIPLINARY TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL (PNOC003)

Neuro-Oncology2021-11-02

CLRM-06. COMPARISON OF INDIVIDUALIZED ANTI-CANCER THERAPY REGIMENS RECOMMENDED BY A MULTIDISCIPLINARY MOLECULARLY-DRIVEN TUMOR BOARD IN A PEDIATRIC DIPG CLINICAL TRIAL (PNOC003) VERSUS THOSE SELECTED BY THE CNS-TAP TOOL

Neuro-Oncology Advances2021-09-21

EPCT-02. COMPARISON OF TARGETED AGENTS RECOMMENDED BY THE CNS-TAP TOOL TO THOSE SELECTED BY A TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL

Neuro-Oncology2021-06-01

Targeted agents recommended by the CNS TAP tool compared to those selected by a tumor board in a molecularly-driven clinical trial in children and young adults with DIPG.

Journal of Clinical Oncology2021-05-20

Precision medicine in recurrent glioblastoma: A feasibility trial conducted by the Ivy Foundation Early Phase Clinical Trials Consortium.

Journal of Clinical Oncology2016-05-204 citations